Showing 4491-4500 of 4926 results for "".
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent
- Galderma Partners with AARS in Support of CDC's "Get Smart About Antibiotics Week"https://practicaldermatology.com/news/20141121-galderma_partners_with_aars_in_support_of_cdcs_get_smart_about_antibiotics_week/2459055/Galderma Laboratories, L.P. joined the American Acne and Rosacea Society (AARS) and the Centers for Disease Control and Prevention's (CDC) Get Smart About Antibiotics Week 2014 (November 17 – 23). AARS and Galderma Laboratories, the first dermatology partner to join with AARS on the initiative, are
- Zeltiq Named Top Medical Devices Company in Deloitte's Technology Fast 500™https://practicaldermatology.com/news/20141117-zeltiq_named_top_medical_devices_company_in__deloittes_technology_fast_500/2459063/Ranked among the top 25 companies in Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America, Zeltiq Aesthetics, Inc. is the top ranked
- Syneron Candela Expands Capabilities of UltraShape Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Powerhttps://practicaldermatology.com/news/20141117-syneron_candela_expands_capabilities_of_ultrashape_platform_receives_fda_clearance_for_the_new_u-sculpt_transducer_and_enhanced_ultrasound_power/2459064/The FDA cleared Syneron Medical Ltd.'s U-Sculpt transducer for the UltraShape non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for a 25 percent increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25 percen
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Foamix Receives USPTO Patents for Topical Tetracyclineshttps://practicaldermatology.com/news/20141113-foamix_receives_uspto_patents_for_topical_tetracyclines/2459066/Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additi
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Study Finds that the Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanomahttps://practicaldermatology.com/news/20141024-study_finds_that_the_use_of_melafind_reduced_benign_biopsies_by_61_in_patients_at_risk_for_melanoma/2459079/The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observati
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be